Hanmi Pharm announced this morning that it has entered into an exclusive licensing agreement with Genentech, part of the Roche Group, covering the development, manufacturing and commercialization of HM17321, Hanmi's long-acting urocortin-2 (UCN2) analog, for obesity and associated conditions including type 2 diabetes and cardiovascular disease. The agreement is worldwide excluding South Korea.

Hanmi receives an upfront payment of USD 190 million, with development, regulatory and commercial milestones taking the total deal package to approximately USD 2.3 billion, and tiered royalties on net sales on top. Hanmi completes the ongoing Phase 1, after which Genentech assumes development from Phase 2 onwards.

This is the first large pharma transaction on a UCN2 asset, and it is the most direct external validation Gubra's GUB-UCN2 program has received to date. HM17321 is, like GUB-UCN2, a CRHR2-selective urocortin-2 analog designed for once-weekly subcutaneous dosing, developed on the same thesis: a non-incretin mechanism that reduces fat mass while preserving or increasing lean mass, with potential as monotherapy and in combination with incretins. Roche's own framing of the rationale, a differentiated approach that selectively reduces fat mass while improving muscle mass and muscle function, is close to the language Gubra has used to describe GUB-UCN2 since the candidate was unveiled.

The deal economics are worth holding up against the AbbVie transaction. Gubra received USD 350 million upfront for ABBV-295 in April 2025, with USD 1,875 million in development and commercialization milestones and royalties on top, for a total package of roughly USD 2.2 billion. Hanmi's package is of similar total size but with a materially lower upfront, which likely reflects both the earlier development stage and the exclusion of South Korea from the license. The read is that big pharma is willing to pay meaningful sums for a Phase 1 stage UCN2 asset before any human efficacy data are available.

For Gubra, the implications cut both ways. On the positive side, GUB-UCN2 is wholly owned and unpartnered, and Gubra has consistently described partnering as the value realization mechanism for its clinical assets. A transaction of this size establishes a reference point for what the market will pay for the mechanism, and it does so before Gubra reports a single data point. It also confirms that the muscle preservation and body composition theme has moved from an investor talking point to something large pharma is willing to underwrite.

On the competitive side, Genentech taking HM17321 forward from Phase 2 means GUB-UCN2 now faces a well-resourced competitor inside the same mechanism, within a Roche cardiometabolic portfolio that already includes petrelintide and CT-388 and therefore offers obvious in-house combination partners. Hanmi's Phase 1 has been running since IND clearance in November 2025, so on the clock HM17321 is somewhat ahead.

The trial designs are not comparable, however, and the positioning differs. Hanmi's ongoing study is a conventional Phase 1 in healthy volunteers and individuals with obesity evaluating safety, tolerability, pharmacokinetics and pharmacodynamics, and Genentech is developing the asset for chronic weight management. Gubra's Phase 1/2a, initiated in July 2026, enrolls approximately 188 participants across healthy volunteers and people living with obesity with and without comorbidities, investigates GUB-UCN2 both standalone and in combination with incretin-based therapy, runs a multiple dose part of up to 16 weeks, and is built around muscle volume and muscle function endpoints. Gubra's stated primary indication is obesity drug-induced muscle loss rather than obesity itself, with management having been explicit that GUB-UCN2 is not being developed as a weight loss drug. Initial data from the single ascending dose part are expected in H1 2027.

The usual caveats apply. Neither asset has reported human efficacy data, both first-in-class claims rest on preclinical work, and the clinical risk in a novel mechanism at this stage remains substantial. What today's announcement changes is not the probability that CRHR2 agonism works in humans, but the evidence on what a validated UCN2 asset is worth to a partner, and the demonstrated appetite among large pharma to acquire one.

We discussed the development on today’s event with Gubra’s management, you can see the event here:

Gubra - Q2 2026 event

Gubra will also host a GUB-UCN2 focused Investor R&D Event on 27 October 2026 in London, where management has indicated it will detail the trial design, endpoints and overall development strategy. Following today's announcement, that event becomes considerably more interesting.

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate visibility subscription agreement. /Michael Friis 11:36 24/08-2026: